Trimodal therapy (TMT) is currently accepted as a suitable alternative to radical cystectomy (RC) with perioperative chemotherapy for muscle-invasive bladder cancer (MIBC). Recent publications demonstrated that survival outcomes are comparable… Click to show full abstract
Trimodal therapy (TMT) is currently accepted as a suitable alternative to radical cystectomy (RC) with perioperative chemotherapy for muscle-invasive bladder cancer (MIBC). Recent publications demonstrated that survival outcomes are comparable when patients are appropriately selected (1,2).
               
Click one of the above tabs to view related content.